New Drug ClassesCOX-2 inhibitors
Section snippets
Screening for COX-1 and COX-2 selectivity
Drugs have been tested for COX-2 selectivity in various systems, including purified recombinant enzyme, transfected cell, and whole-blood assays.9 In the wholeblood assay, synthesis of thromboxane from platelets during clotting is used as an index of COX-1 activity while synthesis of PGE2 (principally from monocytes) in whole blood exposed to lipopolysaccharide is an index of COX-2 activity. Each method gives somewhat different results, probably reflecting differences in protein binding and
COX-1 good, COX-2 bad?
The development of COX-2 inhibitors as potentially gastro-safe NSAIDs is based on the notion that COX-1 predominates in the stomach, yielding protective prostaglandins, while COX-2 is induced in inflammation giving rise to pain, swelling, and stiffness. This concept is flawed. Firstly, most NSAID use is for conditions not regarded as inflammatory; despite this, COX-2 inhibitors are analgesic in such conditions, although their potency is debated. Secondly, the human gastrointestinal tract
Existing drugs
Attempts to explain the toxicity of existing NSAIDs in terms of their COX-2 selectivity have not been successful, which is not surprising since nearly all existing NSAIDs tend to be predominantly COX-1 selective. Of the older NSAIDs, only dicloflenac even approaches equipotency in its effects on COX-1 and COX-2.9 Differences in overall potency of the doses of individual NSAIDs used in practice are more likely important in explaining differences between different NSAIDs in their association with
COX-2 agents
Designer drugs that have emerged from drug-development programmes based on an understanding of the differences between COX-1 and COX-2 are so much more selective than preferential inhibitors that the problem of loss of selectivity at higher doses is unlikely to occur. It has been proposed that the term COX-2 specific inhibitor should be used to describe agents which inhibit COX-2 but have no effect on COX-1 over the whole range of doses used and concentrations achieved in clinical usage.28 One
Alternatives to specific COX-2 inhibitors
It is already clear that COX-2 inhibitors are very likely to have major advantages although these may be counterbalanced to some extent by some limitations. Will other strategies prove better?
Conclusions
COX-2 inhibitors are likely to have a major impact on prescribing in inflammation and analgesia. As their strengths and weakness become clear with continuing use, non-selective NSAIDs with or without coprophylaxis of misoprostol or omeprazole may establish alternative niches. It is too soon to speculate about any possible role for NO-NSAIDs. Paradoxically, the imminent arrival of COX-2 inhibitors appears to have stimulated a move for non-selective NSAIDs from a prescription-only medication
References (75)
- et al.
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
J Biol Chem
(1990) - et al.
TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
J Biol Chem
(1991) - et al.
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors
J Biol Chem
(1996) - et al.
COX-1 expression in human gastric mucosa infected with Helicobacter pylori: constitutive or induced?
Gastroenterology
(1998) - et al.
A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee
Osteoarthritis Cartilage
(1997) - et al.
Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1
Eur J Pharmacol
(1995) - et al.
Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
Gastroenterology
(1997) - et al.
Hypoxia induces cyclooxygenase-2 via the NF-KappaB pbs transcription facts in human vascular endothelial cells
J Biol Chem
(1997) - et al.
Cyclooxygenase-1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity
Gastroenterology
(1998) - et al.
Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen
Gastroenterology
(1998)
Future treatments for arthritis—new NSAIDs, NO-NSAIDs or no NSAIDs?
Gastroenterology
A nitirc oxidereleasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats
Gastroenterology
NSAIDs and CagA positive H pylori but not CagA negative H pylori as independent risk factors for bleeding peptic ulcers
Gastroenterology
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Nature
The structure of human cyclooxygenase-2; conservation and flexibility of the NSAID binding site
Nat Struct Biol
Investigation of the binding of isoform-selective inhibitors to prostaglandin endoperoxide synthases using fluorescence spectroscopy
Biochemistry
New highly selective COX-2 inhibitors
Anti-inflammatory and safety profile of DuP697, a novel orally effective prostaglandin synthesis inhibiton
J Pharmacol Exp Ther
Differential inhibition of COX-1 and COX-2 by NSAIDs: a summary of results obtained using various test systems
Meloxicam
Drugs
Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
J Physiol Pharmacol
A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip
Br J Rheumatol
Meloxicam in osteoarthritis: a six months, double-blind comparison with diclofenac sodium
Br J Rheumatol
Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double-blind study
Clin Drug Invest
A six months double-blind trial to compare the efficacy and safety of meloxicam 7·5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis
Br J Rheumatol
A four-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7·5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoxcopy and symptoms evaluation in healthy volunteer
Br J Rheumatol
Global analysis of safety of a new NSAID, meloxicam
Br J Rheumatol
Gastrointestinal tolerabability of the COX-2 inhibitor, meloxicam, in osteoarthritis patients: the meloxicam large scale internatinal study safety assessment (MELISSA)
Br J Rheumatol
Improvement in gastrointestinal tolerabilityof the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis
Br J Rheumatol
Nimesulide: an update on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
Drugs
Activity of nimesulide on constitutive and inducible cyclooxygenases
Arzneimittelforschung
Risk of hospitalisation for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
Arch Intern Med
NSAIDs, COX-2 inhibitors, and the gut
Lancet
Effects of nabumetone on prostanoid synthesis in humans
Clin Pharmacol Ther
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y]benzenesulfonamide (SC-58635, celecoxib)
J Med Chem
Specific COX-2 inhibitors: from bench to bedside
Cited by (1090)
Potentially active aspirin derivative to release nitric oxide: In-vitro, in-vivo and in-silico approaches
2024, Saudi Pharmaceutical JournalAntioxidant and anti-inflammatory potential of rhizome aqueous extract of sea holly (Eryngium maritimum L.) on Jurkat cells
2023, Journal of EthnopharmacologyIntegrating in vivo and in silico approaches to investigate the potential of Zingiber roseum rhizome extract against pyrexia, inflammation and pain
2023, Saudi Journal of Biological SciencesDevelopment of novel pyrazole, imidazo[1,2-b]pyrazole, and pyrazolo[1,5-a]pyrimidine derivatives as a new class of COX-2 inhibitors with immunomodulatory potential
2023, European Journal of Medicinal Chemistry